Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SANDOZ CLOZARIL MANDATORY BLOOD MONITORING PROGRAM

Executive Summary

SANDOZ CLOZARIL MANDATORY BLOOD MONITORING PROGRAM is being pilot tested as a means of reducing the risk of agranulocytosis among the drug's target population of treatment-resistant schizophrenics. Under the test program, which was described May 8 at the annual meeting of the American Psychiatrist Association in Montreal, all patients receiving the drug will be required to have blood drawn at least once a week prior to receiving an additional seven-day supply of Clozaril (clozapine). The unique patient monitoring requirement proposed for the anti-psychotic agent is in response to concerns about agranulocytosis, a potentially fatal side effect which occurs in roughly 1% - 2% of patients taking Clozaril. The program grew out of Sandoz' experience with patients enrolled in its clinical trials and "compassionate use" IND for the drug, Sandoz senior associate director of clinical research Gilbert Honigfeld, PhD, told "The Pink Sheet." It is also used in the European marketing of the anti-psychotic agent. "Our experience has been that physicians become somewhat lax after they get experienced using the drug" in keeping track of patients' white blood cell counts (WBC), Honigfeld commented. For those few individuals at risk for agranulocytosis, the condition can be reversed if caught at the initial signs of WBC suppression, he added. Pilot testing is beginning at about five clinical centers around the country. The program will be expanded in the coming months. It could be implemented nationally if Clozaril gains FDA approval, expected late this year or in early 1989. If the restricted distribution format proves feasible it will be a "major departure from other new drug introductions," Honigfield maintained. It will enable Sandoz to provide "100% coverage" in its subsequent post-approval reporting to FDA, he said. The monitoring will be administered for Sandoz by a national home health care organization in conjunction with a national clinic laboratory company, Honigfeld explained. "Case administrators" from the home health agency will handle enrollment procedures for patients referred by physicians. The case worker will also arrange for time and locations for the blood sampling. Any indication of WBC suppression will be reported to the doctor. Distribution of the drug will also be handled through the home health agency, Honigfeld explained. Costs for mandatory monitoring are expected to be incorporated in Clozaril's pricing structure. To provide additional justification for the predicated premium price, Sandoz commissioned a study on the "Economic Costs of Treatment-resistant Schizophrenia." Bryan Luce, with the Battelle Institute, presented the cost estimates at the APA meeting. Based on a literature review, he found that "drug trial data suggest 10%-20% [of the] schizophrenic population" does not respond to current anti-psychotic agents. That works out to between 240,000 and 480,000 patients, he added. Direct costs for treating refractor patients range from $ 16,263 to $ 58,418 per year, Luce reported. Lost earnings cost the economy another $ 16,991 annually per patient, another study suggested. Estimates on the overall costs for refractory schizophrenics in the U.S. range from $ 14 billion to over $ 28 billion a year, he said.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel